TELA Bio rolls out new OviTex resorbable for implantation

TELA Bio rolls out new OviTex resorbable for implantation

Time Stamp: August 17, 2023 3:21 AM
Source Node: 2827185

<!–

–>

OviTex PRS is claimed to be the only biologic reinforced with interwoven polymer sutures designed for plastic and reconstructive surgery. Credit: JAFAR AHMED on Unsplash.

Medical technology company TELA Bio has introduced its new OviTex PRS Long-Term Resorbable product in the US for implantation.

OviTex PRS has been developed for implantation to bolster soft tissue in weak patients who need tissue repair or reinforcement in plastic and reconstructive surgery.

The device is delivered in a sterile state and is designed for single-use purposes.

It comes with specific design features, including bi-directional stretch and a completely resorbable, long-term polymer for reinforcement.

It supplements the existing OviTex PRS products of the company, which encompass both short-term and permanent resorbable configurations of OviTex PRS.

TELA Bio president and CEO Antony Koblish said: “We are excited to offer expanded clinical utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery.

“OviTex PRS Long-Term Resorbable is an important addition to the portfolio as it will allow surgeons to address clinical indications that require longer-term reinforcement while avoiding the use of permanent materials.”

The company has developed the OviTex PRS portfolio to enhance outcomes by enabling the remodelling of functional tissue while controlling the stretch degree and direction.

OviTex PRS is claimed to be the only biologic reinforced with interwoven polymer sutures developed particularly for plastic and reconstructive surgery.

To meet the specific requirements of each patient, the OviTex PRS portfolio provides several resorption, stretch and shape offerings.

University of Rochester Medical Center Plastic Surgery Professor Dr Howard Langstein said: “My experience with OviTex PRS has been very positive and the addition of a long-term resorbable reinforcement option further expands the treatment options for my patients.”

<!– GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] —

googletag.cmd.push(function() { googletag.display(‘div-gpt-ad-8581390-1’); });

!– End AdSlot 3 –>

Time Stamp:

More from Medical Device Network